In short
Bladder cancer diagnosis involves several tests and procedures to confirm the disease and determine its extent. Early detection through proper diagnostic methods can significantly improve treatment outcomes and help doctors create the most effective care plan for each patient.
Key points
- Blood in your urine should never be ignored, even if it disappears on its own, as it is the most common warning sign of bladder cancer.
- Cystoscopy, where a thin tube with a camera is inserted into your bladder, remains the gold standard for detecting bladder cancer and can also be used to take tissue samples.
- Early detection dramatically improves survival rates, with 96% of patients surviving at least five years when cancer is caught in the innermost layer of the bladder.
- Bladder cancer has a remarkably high recurrence rate of about 75% for early-stage disease, making long-term surveillance essential even after successful treatment.
- Men are four times more likely to develop bladder cancer than women, but women tend to be diagnosed at more advanced stages because they may overlook symptoms.
- The grade and stage of your cancer determine your treatment plan, with grade indicating how aggressive the cells look and stage showing how far the cancer has spread.
- Advanced imaging tests like CT and MRI scans help doctors see whether cancer has spread beyond the bladder to lymph nodes or other organs.
- Clinical trials require specific diagnostic criteria for enrollment, including confirmed biopsy results and imaging documentation of disease extent.
Introduction: Who Should Undergo Diagnostics
Anyone experiencing certain warning signs should seek medical evaluation for possible bladder cancer. The most common symptom that prompts people to see a doctor is blood in the urine, which might be visible to the naked eye or only detectable under a microscope. This symptom, known as hematuria, can appear and disappear, but even if it goes away on its own, it still requires medical attention.
Other symptoms that should lead you to seek diagnostic testing include frequent urination, painful urination when you pee, or unexplained back pain. While these symptoms can be caused by many other conditions like urinary tract infections or kidney stones, they need proper evaluation to rule out bladder cancer.
Adults aged 35 years and older who notice blood in their urine should undergo evaluation with diagnostic tests. Younger people should also be tested if they have irritative voiding symptoms, known risk factors for bladder cancer, or visible blood in their urine at any age.
Because bladder cancer is the fourth most common cancer in men and they are four times more likely to develop it than women, older men, especially those who smoke, should be particularly vigilant about symptoms. However, women should not ignore these signs either, as they tend to be diagnosed at more advanced stages because they may not be as aware of bladder cancer symptoms.
Classic Diagnostic Methods
When you visit your doctor with symptoms that might suggest bladder cancer, they will use several diagnostic methods to determine whether cancer is present and, if so, what type and stage it is. The diagnostic process typically involves multiple steps and different types of tests.
Initial Medical History and Physical Examination
Your doctor will start by asking detailed questions about your symptoms, how long you've had them, and whether you have any risk factors for bladder cancer such as smoking history or exposure to certain chemicals. They may also perform a physical examination, which could include a digital rectal exam where the doctor inserts a gloved finger into the rectum to feel for abnormalities in the bladder and surrounding organs.
Urine Tests
A simple urine test, called urinalysis, is often one of the first diagnostic tools used. This test examines your urine for blood, infection, and abnormal cells. If blood is found in your urine, it doesn't automatically mean you have cancer, as many other conditions can cause this symptom. However, it does signal the need for further investigation.
Cystoscopy
Cystoscopy is the most important diagnostic procedure for detecting bladder cancer. During this test, your doctor inserts a thin, lighted tube called a cystoscope through your urethra into your bladder. This allows them to look directly at the inside of your bladder and see if there are any tumors or abnormal areas.
The procedure can be done in the doctor's office or an operating room. If the doctor sees anything suspicious during the cystoscopy, they can take small tissue samples, called biopsies, for further examination under a microscope. Some medical centers use a special technique called blue light cystoscopy, which makes it easier to see certain types of tumors that might be missed with regular white light.
Transurethral Resection of Bladder Tumor (TURBT)
If a tumor is found during cystoscopy, the next step is usually a procedure called transurethral resection or TURBT. This procedure serves three important purposes: it provides a definitive diagnosis, helps determine the stage of the cancer, and can actually remove the tumor as part of the initial treatment.
During TURBT, the doctor uses a special tool inserted through the cystoscope to remove the tumor or burn it away using high-energy electricity, a technique called fulguration. The removed tissue is then sent to a laboratory where specialists examine it to determine the exact type of cancer cells and how abnormal they are, which is called the grade.
Imaging Tests
To check whether cancer has spread beyond the bladder and to examine the upper urinary tract, doctors use various imaging tests. These might include computed tomography (CT) scans, magnetic resonance imaging (MRI), or ultrasound. These tests create detailed pictures of your bladder, kidneys, ureters, and surrounding tissues.
CT scans are particularly useful because they can show whether the cancer has invaded the muscle layer of the bladder wall or spread to nearby lymph nodes or other organs. An MRI might be used in certain situations to get even more detailed images of the bladder and surrounding structures.
Kidney function testing is also part of the evaluation, as it helps doctors understand how well your kidneys are working and plan appropriate treatment. This typically involves blood tests that measure certain substances in your blood.
Understanding Cancer Grade and Stage
Once cancer is confirmed, doctors need to determine two important characteristics: the grade and the stage. The grade refers to how abnormal the cancer cells look under a microscope. Bladder cancers are generally classified as low grade or high grade, with high-grade cancers being more aggressive and more likely to spread.
The stage describes how far the cancer has grown into the bladder wall and whether it has spread to other areas. Bladder cancer can be categorized as noninvasive (only on or near the surface), non-muscle-invasive (has moved deeper but not into muscle), or muscle-invasive (has grown into the bladder muscle and possibly beyond).
Understanding both the grade and stage is crucial because they determine what type of treatment you will receive and help predict your outlook. Your doctor will use all the information from your tests to classify your cancer according to a system called TNM staging, which looks at the tumor size and extent, lymph node involvement, and whether there are distant metastases.
Diagnostics for Clinical Trial Qualification
When patients are being considered for enrollment in clinical trials for bladder cancer, they must undergo specific diagnostic tests that serve as standard criteria for qualification. These tests help researchers ensure that participants meet the specific requirements of the study and that they can safely participate.
Clinical trials often require a confirmed diagnosis of bladder cancer through biopsy results showing the specific type of cancer cells. Most commonly, this would be urothelial carcinoma, which accounts for more than 90% of bladder cancers in industrialized nations. The stage of the cancer is also critical, as many trials are designed specifically for either non-muscle-invasive or muscle-invasive disease.
Imaging tests such as CT scans, MRI, or ultrasound are typically required to document the extent of the disease before enrolling in a trial. These baseline images allow researchers to track whether the treatment being studied is having any effect on the cancer over time. For trials involving muscle-invasive bladder cancer, patients usually need documented evidence that the cancer has penetrated the bladder's muscular wall.
Blood tests and kidney function assessments are standard requirements for most bladder cancer trials. These tests help determine whether patients are healthy enough to tolerate the experimental treatments being studied. Researchers need to know that a patient's kidneys, liver, and other organs are functioning well enough to process the drugs or therapies being tested.
For patients who have previously received treatment, documentation of how their cancer responded to prior therapies is often required. This might include records showing that the cancer came back after initial treatment with immunotherapy drugs like Bacillus Calmette-Guérin (BCG), which is commonly used for non-muscle-invasive bladder cancer. Some trials specifically target patients whose cancer did not respond to standard treatments.
Recent clinical trials, such as the SunRISe-1 trial, required participants to have high-risk non-muscle-invasive bladder cancer that had returned after treatment with BCG. The trial used diagnostic procedures to confirm that all 85 enrolled patients met these specific criteria before they could receive the experimental treatment being studied.
Many trials also require that patients have measurable disease, meaning the tumors can be clearly seen and measured on imaging tests or during cystoscopy. This allows researchers to objectively assess whether the treatment is shrinking the tumors, stopping their growth, or having no effect. Regular follow-up cystoscopies and imaging tests are typically scheduled throughout the trial to monitor progress.
Prognosis and Survival Rate
Prognosis
The outlook for patients with bladder cancer depends heavily on when the disease is detected and how far it has spread. Early-stage bladder cancer that is caught and treated before it spreads generally has a much better prognosis than cancer that has already invaded deeper tissues or spread to other parts of the body. However, one significant challenge with bladder cancer is its tendency to come back even after successful treatment. About 75% of early-stage bladder cancers recur, which means patients need to remain vigilant and attend regular follow-up appointments with their healthcare providers.
The grade of the cancer also affects prognosis. High-grade tumors, which have more abnormal-looking cells, are more aggressive and more likely to invade the muscle layer of the bladder or spread to other areas. Low-grade tumors tend to grow more slowly and are less likely to spread, giving patients a better outlook.
For non-muscle-invasive bladder cancer, which makes up approximately 70% of cases, patients have a high recurrence rate of up to 70% within two years of treatment. This doesn't necessarily mean the cancer becomes life-threatening, but it does require ongoing monitoring through regular cystoscopy exams and possibly additional treatments.
Muscle-invasive bladder cancer and cancer that has spread beyond the bladder have a more serious prognosis and typically require more aggressive treatment, such as removal of the bladder or radiation therapy combined with chemotherapy. The earlier these advanced cancers are detected and treated, the better the chances of controlling the disease.
Survival rate
Survival rates for bladder cancer vary significantly depending on the stage of the disease when it is diagnosed. When bladder cancer is caught at an early stage, survival rates are quite encouraging. For tumors that are restricted to the inner layer of the bladder, the 5-year relative survival rate is 96%. This means that 96% of patients with this early-stage cancer are still alive five years after diagnosis.
When the disease is localized to the bladder but has grown deeper into the bladder wall, the 5-year relative survival rate is 70%. This still represents a majority of patients surviving at least five years, highlighting the importance of catching the cancer before it spreads beyond the bladder.
Unfortunately, survival rates drop significantly when bladder cancer spreads beyond the bladder to nearby tissues or organs. For disease that has spread locally beyond the bladder, the 5-year relative survival rate falls to 34%. When cancer has spread to distant parts of the body, such as the lungs, liver, or bones, the 5-year relative survival rate is only 5%.
It's important to understand that these statistics represent averages based on large groups of patients and may not predict exactly what will happen to any individual person. Many factors affect survival, including the specific type of bladder cancer, the patient's overall health, how well the cancer responds to treatment, and advances in treatment options that continue to improve outcomes for patients.
The high recurrence rate of bladder cancer, even after successful treatment, means that long-term survival requires ongoing surveillance and follow-up care. Patients who remain vigilant about attending scheduled follow-up appointments and reporting new symptoms promptly have the best chance of catching any recurrence early when it is most treatable.
